Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature

Immunotherapy with immune checkpoint inhibitors (ICIs), including programmed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors, has revolutionized the systematic treatment of advanced and metastatic solid tumors. However, the response rate to ICIs is unsatisfactory, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Dongfeng, Guan, Yaping, Liu, Mingguo, He, Shuqian, Zhao, Weipeng, Yin, Beibei, Liang, Jing, Li, Yan, Wang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201609/
https://www.ncbi.nlm.nih.gov/pubmed/34135884
http://dx.doi.org/10.3389/fimmu.2021.608292

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201609/
https://www.ncbi.nlm.nih.gov/pubmed/34135884
http://dx.doi.org/10.3389/fimmu.2021.608292

Ejemplares similares